1. Home
  2. CABR vs HIND Comparison

CABR vs HIND Comparison

Compare CABR & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caring Brands Inc.

CABR

Caring Brands Inc.

HOLD

Current Price

$1.40

Market Cap

13.1M

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

N/A

Current Price

$2.00

Market Cap

15.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CABR
HIND
Founded
2020
2017
Country
United States
United States
Employees
N/A
2
Industry
Package Goods/Cosmetics
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
13.1M
15.2M
IPO Year
2025
2016

Fundamental Metrics

Financial Performance
Metric
CABR
HIND
Price
$1.40
$2.00
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
38.8K
4.7K
Earning Date
05-15-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
64.86
EPS
N/A
N/A
Revenue
$4,215.00
$319,714.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.43
52 Week Low
$0.71
$1.75
52 Week High
$1.84
$6.56

Technical Indicators

Market Signals
Indicator
CABR
HIND
Relative Strength Index (RSI) 56.79 37.55
Support Level $1.24 $1.99
Resistance Level $1.58 $2.32
Average True Range (ATR) 0.12 0.07
MACD 0.02 -0.02
Stochastic Oscillator 66.04 14.07

Price Performance

Historical Comparison
CABR
HIND

About CABR Caring Brands Inc.

Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: